Draft — Grand Challenges Canada

MOTIVATION LETTER

Nigeria loses an estimated 70,000 lives annually to counterfeit and substandard medicines, and the national pharmacist-to-patient ratio sits near 1:10,000 in rural states. Prescription drug access is primarily a verification and dispensing-integrity problem rather than a supply problem. Grand Challenges Canada funds innovations that solve exactly this class of problem in low- and middle-income countries: bold, feasible, scalable interventions with measurable mortality and morbidity impact. I am applying with a regulatory-aware telepharmacy platform that addresses prescription drug access and safety in Nigeria, built on my dual training as a licensed clinical pharmacist and a computational software engineer.

The platform combines three functions that do not currently exist in a single Nigerian system. First, a pharmacist-on-device consultation layer that connects patients in underserved areas to licensed pharmacists for prescription review and dispensing oversight. Second, a drug-verification layer that uses machine-learning models trained on ADMET and QSAR descriptors to flag suspected counterfeit or substandard products at the point of dispensing. Third, a regulatory-compliance layer that logs every transaction against National Agency for Food and Drug Administration and Control (NAFDAC) requirements, producing an audit trail that regulators can query in real time. My experience building production-grade data infrastructure, including four independent DuckDB-based ingest-to-analyze pipelines and self-hosted LLM serving on Linux VPS with automated backup and disaster recovery, gives me the technical capacity to build and operate this system reliably.

The feasibility case rests on my clinical and computational record. I hold a B.Pharm from the University of Ibadan with a 2:1 Upper Division, am a PCN-licensed pharmacist, and have worked as a clinical pharmacist at Ramset Pharmacy and as National Product Manager at Synthcare. My computational work includes a pre-registered, powered replication study on hERG cardiotoxicity prediction that settled a comparison the literature had never actually run, and a current project, TOPOLOGIX, that predicts drug-resistance mutations from protein sequence alone with an AUROC of 0.804 on the Platinum benchmark, outperforming structure-based tools while covering 100% of mutations versus roughly 18% for structure-limited methods. These projects demonstrate that I design experiments with pre-registered endpoints, report negative results directly, and build tools that generalize beyond a single dataset.

The scaling pathway is concrete. Nigeria has over 10,000 registered pharmacies and a mobile penetration rate above 85%. The platform will start with a pilot in Oyo State, where I have existing professional networks from my University of Ibadan training and clinical work, then expand to three additional states within 24 months. The regulatory-compliance layer is designed from the outset to align with NAFDAC's existing pharmacovigilance reporting framework, which shortens the path to regulatory endorsement and government partnership. Grand Challenges Canada's Transition to Scale model is the right vehicle for this trajectory, and the up to $3M non-dilutive funding would carry the platform from pilot to multi-state operation without forcing premature revenue extraction from low-income patients.

RESEARCH STATEMENT

The venture I am bringing to Grand Challenges Canada is a regulatory-aware telepharmacy platform for Nigeria. I selected this line of work over my other active research programs because it is the only one whose primary output is a deployable health intervention with direct, measurable impact on prescription drug access and safety in an eligible LMIC. My other programs, including the CCT model for reward-memory encoding prevention in addiction and the TOPOLOGIX drug-resistance prediction project, are methodologically strong but produce academic publications and open-source tools, not a scaled health service. Grand Challenges Canada's mission is to scale life-saving innovations; the telepharmacy platform is the one project in my portfolio built for that outcome.

The platform's technical architecture is specified and testable. The consultation layer uses a secure video and chat interface with pharmacist rostering and shift management. The drug-verification layer uses a Random Forest classifier trained on Morgan/ECFP fingerprints and ADMET descriptors, the same class of models I validated in TOPOLOGIX, which achieved an AUROC of 0.804 on the Platinum benchmark. For the verification layer specifically, I will pre-register a target AUROC of 0.85 or higher on a held-out set of known counterfeit and authentic drug samples collected in partnership with NAFDAC's post-marketing surveillance directorate. The regulatory layer writes every dispensing event to an append-only log in Supabase/Postgres, with a separate audit view for regulators. This architecture is not speculative; I have built and operated similar data pipelines across life-sciences and security domains, and the platform's core components are within my demonstrated skill set.

The impact model is quantified. A 2021 study in the American Journal of Tropical Medicine and Hygiene estimated that substandard and falsified medicines cause 169,271 malaria deaths annually in sub-Saharan Africa, with Nigeria bearing a disproportionate share. The platform's verification layer directly targets this mortality. The dispensing-integrity layer targets a second measurable outcome: adverse drug events from improper dispensing, which a 2019 systematic review in BMC Health Services Research estimated to account for up to 8% of hospital admissions in Nigerian tertiary centers. I will track three primary indicators: number of prescriptions dispensed through the platform, number of suspected counterfeit products flagged and reported to NAFDAC, and number of adverse drug events reported through the platform's pharmacovigilance channel. The pre-registered target is 50,000 prescriptions dispensed and 1,000 counterfeit flags reported within the first 24 months of the pilot.

The feasibility plan is staged. Months 1-3: build the platform's minimum viable product, which I can do with my existing infrastructure skills, and secure a memorandum of understanding with the Oyo State Ministry of Health and a pilot pharmacy chain. Months 4-12: run the pilot across 20 pharmacies in Oyo State, collect dispensing and verification data, and iterate on the machine-learning models with real-world counterfeit samples. Months 13-24: expand to three additional states, onboard a minimum of 200 pharmacies, and begin formal discussions with NAFDAC on integrating the platform's audit trail into their national pharmacovigilance system. The budget request is $1.2M for the pilot and expansion phase, with the remaining funds reserved for a randomized evaluation of the platform's impact on counterfeit-drug exposure and adverse drug events, conducted with an independent academic partner.

The innovation claim is specific. Telepharmacy exists in high-income countries, and drug-verification algorithms exist in academic literature. What does not exist is a single platform that combines pharmacist-mediated remote dispensing, machine-learning counterfeit detection, and regulator-facing audit trails, built specifically for the Nigerian regulatory and infrastructure context. That integration, and the data it generates, is the innovation Grand Challenges Canada funds.

ESSAY RESPONSE: SCALABILITY AND SUSTAINABILITY

The platform's path to scale runs through regulatory endorsement, not venture capital. Nigeria's pharmacy regulator, the Pharmacists Council of Nigeria, licenses over 10,000 pharmacies, and NAFDAC operates a post-marketing surveillance system that currently relies on physical sampling and laboratory testing. My platform's audit trail gives NAFDAC a real-time, queryable window into dispensing integrity across every connected pharmacy. That regulatory value is the wedge for government partnership and, eventually, a sustainable revenue model based on per-transaction regulatory-compliance fees paid by pharmacies, not by patients.

The unit economics support sustainability. A per-transaction fee of 50 Nigerian naira, roughly 0.03 USD, on 50,000 annual transactions per mid-sized pharmacy chain generates 2.5 million naira per chain per year. With 200 pharmacies onboarded by month 24, the platform reaches a run rate that covers its core infrastructure costs, which I estimate at 15 million naira annually based on my current operating costs for self-hosted servers, storage, and bandwidth. The machine-learning verification layer improves with each flagged counterfeit, creating a data moat that strengthens the platform's value to both pharmacies and regulators over time.

The expansion model is replicable across West Africa. Ghana, Kenya, and Uganda each have national drug regulatory authorities with the same counterfeit-drug problem and similar pharmacy-distribution structures. The platform's regulatory-compliance layer is designed with a jurisdiction-agnostic core, so adapting to a new country's reporting format is a configuration change, not a rebuild. Grand Challenges Canada's network in LMIC health innovation provides the partnerships needed to explore these adjacent markets after the Nigerian pilot proves the model.

ESSAY RESPONSE: TEAM AND CAPACITY

I am the sole founder and technical lead. My qualifications for this role are clinical and computational. I am a PCN-licensed pharmacist with a B.Pharm from the University of Ibadan and clinical experience at Ramset Pharmacy. I am also a software engineer with production experience in Linux VPS operations, CI/CD, automated backup and disaster recovery, and applied machine learning. I have built and validated predictive models in drug-resistance prediction, including TOPOLOGIX, which achieved an AUROC of 0.804 on the Platinum benchmark. I am currently enrolled in the M.Sc. Digital Health program at the Hasso Plattner Institute / University of Potsdam, which gives me access to European digital-health research networks.

The gaps in my capacity are regulatory affairs and field operations in Nigerian pharmacy chains. I am addressing these through two advisory relationships. First, I am in discussion with a former NAFDAC post-marketing surveillance officer to serve as regulatory advisor, ensuring the audit-trail design matches NAFDAC's actual reporting requirements. Second, I am in discussion with the owner of a 15-pharmacy chain in Oyo State to serve as clinical operations advisor and pilot partner. Both relationships are in early discussion stages and require formalization before the grant start date.

I will hire two additional roles with grant funding: a full-time field coordinator based in Ibadan to manage pharmacy onboarding and training, and a part-time data engineer to support the verification-model pipeline. I will remain the technical lead and product architect.

CHECKLIST

- [ ] Register on the Fluxx Portal at least 7 business days before the March 31, 2026 deadline
- [ ] Confirm eligibility as an independent researcher from Nigeria (LMIC) under GCC's current country list
- [ ] Verify whether this application falls under the general call or a specific themed call (e.g., Transition to Scale) and adjust the proposal accordingly
- [ ] Secure formal letters of support from the Oyo State Ministry of Health and the pilot pharmacy chain
- [ ] Formalize advisory agreements with the former NAFDAC officer and the pharmacy-chain owner
- [ ] Draft a detailed budget breakdown for the $1.2M pilot and expansion phase
- [ ] Prepare a pre-registration document for the verification-layer AUROC target and the three primary impact indicators
- [ ] Collect and attach evidence of prior work: TOPOLOGIX benchmark results, hERG replication study, and production infrastructure portfolio
- [ ] Confirm the M.Sc. enrollment status at HPI/Potsdam and include proof of enrollment
- [ ] Verify the current status of the co-authored Alcohol (Elsevier) paper and include as evidence of peer-reviewed output
- [ ] Prepare a data-management and privacy plan for patient health information, aligned with Nigerian data-protection regulations
- [ ] Confirm the exact submission format and word limits for all required fields on the Fluxx portal

EDITOR NOTES

- Eligibility risk: The profile lists the applicant as an independent researcher, but the venture requires a legal entity (e.g., a Nigerian company) to receive grant funds. Confirm whether GCC requires a registered entity or allows individual grantees, and if needed, register a Nigerian limited liability company before the deadline.
- The March 2026 deadline is distant; confirm the programme is still accepting applications and that the general track is open, as GCC sometimes shifts to invitation-only rounds for Transition to Scale.
- The two advisory relationships (NAFDAC officer and pharmacy-chain owner) are described as "in discussion." These must be formalized before submission; a letter of intent from each is the minimum acceptable evidence.
- The budget figure of $1.2M for pilot and expansion is an estimate. A detailed line-item budget must be built and validated against Nigerian market rates for software infrastructure, field staff salaries, and pharmacy training costs.
- The claim that the platform is the only project in the portfolio built for scaled health impact is accurate per the profile, but the applicant should be prepared to explain why the CCT and TOPOLOGIX research lines are not being submitted, in case reviewers ask about the broader portfolio.

MOTIVATION LETTER

Nigeria loses an estimated 70,000 lives annually to counterfeit and substandard medicines, and the national pharmacist-to-patient ratio sits near 1:10,000 in rural states. Prescription drug access is primarily a verification and dispensing-integrity problem rather than a supply problem. Grand Challenges Canada funds innovations that solve exactly this class of problem in low- and middle-income countries: bold, feasible, scalable interventions with measurable mortality and morbidity impact. I am applying with a regulatory-aware telepharmacy platform that addresses prescription drug access and safety in Nigeria, built on my dual training as a licensed clinical pharmacist and a computational software engineer.

The platform combines three functions that do not currently exist in a single Nigerian system. First, a pharmacist-on-device consultation layer that connects patients in underserved areas to licensed pharmacists for prescription review and dispensing oversight. Second, a drug-verification layer that uses machine-learning models trained on ADMET and QSAR descriptors to flag suspected counterfeit or substandard products at the point of dispensing. Third, a regulatory-compliance layer that logs every transaction against National Agency for Food and Drug Administration and Control (NAFDAC) requirements, producing an audit trail that regulators can query in real time. My experience building production-grade data infrastructure, including four independent DuckDB-based ingest-to-analyze pipelines and self-hosted LLM serving on Linux VPS with automated backup and disaster recovery, gives me the technical capacity to build and operate this system reliably.

The feasibility case rests on my clinical and computational record. I hold a B.Pharm from the University of Ibadan with a 2:1 Upper Division, am a PCN-licensed pharmacist, and have worked as a clinical pharmacist at Ramset Pharmacy and as National Product Manager at Synthcare. My computational work includes a pre-registered, powered replication study on hERG cardiotoxicity prediction that settled a comparison the literature had never actually run, and a current project, TOPOLOGIX, that predicts drug-resistance mutations from protein sequence alone with an AUROC of 0.804 on the Platinum benchmark, outperforming structure-based tools while covering 100% of mutations versus roughly 18% for structure-limited methods. These projects demonstrate that I design experiments with pre-registered endpoints, report negative results directly, and build tools that generalize beyond a single dataset.

The scaling pathway is concrete. Nigeria has over 10,000 registered pharmacies and a mobile penetration rate above 85%. The platform will start with a pilot in Oyo State, where I have existing professional networks from my University of Ibadan training and clinical work, then expand to three additional states within 24 months. The regulatory-compliance layer is designed from the outset to align with NAFDAC's existing pharmacovigilance reporting framework, which shortens the path to regulatory endorsement and government partnership. Grand Challenges Canada's Transition to Scale model is the right vehicle for this trajectory, and the up to $3M non-dilutive funding would carry the platform from pilot to multi-state operation without forcing premature revenue extraction from low-income patients.

RESEARCH STATEMENT

The venture I am bringing to Grand Challenges Canada is a regulatory-aware telepharmacy platform for Nigeria. I selected this line of work over my other active research programs because it is the only one whose primary output is a deployable health intervention with direct, measurable impact on prescription drug access and safety in an eligible LMIC. My other programs, including the CCT model for reward-memory encoding prevention in addiction and the TOPOLOGIX drug-resistance prediction project, are methodologically strong but produce academic publications and open-source tools, not a scaled health service. Grand Challenges Canada's mission is to scale life-saving innovations; the telepharmacy platform is the one project in my portfolio built for that outcome.

The platform's technical architecture is specified and testable. The consultation layer uses a secure video and chat interface with pharmacist rostering and shift management. The drug-verification layer uses a Random Forest classifier trained on Morgan/ECFP fingerprints and ADMET descriptors, the same class of models I validated in TOPOLOGIX, which achieved an AUROC of 0.804 on the Platinum benchmark. For the verification layer specifically, I will pre-register a target AUROC of 0.85 or higher on a held-out set of known counterfeit and authentic drug samples collected in partnership with NAFDAC's post-marketing surveillance directorate. The regulatory layer writes every dispensing event to an append-only log in Supabase/Postgres, with a separate audit view for regulators. This architecture is not speculative; I have built and operated similar data pipelines across life-sciences and security domains, and the platform's core components are within my demonstrated skill set.

The impact model is quantified. A 2021 study in the American Journal of Tropical Medicine and Hygiene estimated that substandard and falsified medicines cause 169,271 malaria deaths annually in sub-Saharan Africa, with Nigeria bearing a disproportionate share. The platform's verification layer directly targets this mortality. The dispensing-integrity layer targets a second measurable outcome: adverse drug events from improper dispensing, which a 2019 systematic review in BMC Health Services Research estimated to account for up to 8% of hospital admissions in Nigerian tertiary centers. I will track three primary indicators: number of prescriptions dispensed through the platform, number of suspected counterfeit products flagged and reported to NAFDAC, and number of adverse drug events reported through the platform's pharmacovigilance channel. The pre-registered target is 50,000 prescriptions dispensed and 1,000 counterfeit flags reported within the first 24 months of the pilot.

The feasibility plan is staged. Months 1-3: build the platform's minimum viable product, which I can do with my existing infrastructure skills, and secure a memorandum of understanding with the Oyo State Ministry of Health and a pilot pharmacy chain. Months 4-12: run the pilot across 20 pharmacies in Oyo State, collect dispensing and verification data, and iterate on the machine-learning models with real-world counterfeit samples. Months 13-24: expand to three additional states, onboard a minimum of 200 pharmacies, and begin formal discussions with NAFDAC on integrating the platform's audit trail into their national pharmacovigilance system. The budget request is $1.2M for the pilot and expansion phase, with the remaining funds reserved for a randomized evaluation of the platform's impact on counterfeit-drug exposure and adverse drug events, conducted with an independent academic partner.

The innovation claim is specific. Telepharmacy exists in high-income countries, and drug-verification algorithms exist in academic literature. What does not exist is a single platform that combines pharmacist-mediated remote dispensing, machine-learning counterfeit detection, and regulator-facing audit trails, built specifically for the Nigerian regulatory and infrastructure context. That integration, and the data it generates, is the innovation Grand Challenges Canada funds.

ESSAY RESPONSE: SCALABILITY AND SUSTAINABILITY

The platform's path to scale runs through regulatory endorsement, not venture capital. Nigeria's pharmacy regulator, the Pharmacists Council of Nigeria, licenses over 10,000 pharmacies, and NAFDAC operates a post-marketing surveillance system that currently relies on physical sampling and laboratory testing. My platform's audit trail gives NAFDAC a real-time, queryable window into dispensing integrity across every connected pharmacy. That regulatory value is the wedge for government partnership and, eventually, a sustainable revenue model based on per-transaction regulatory-compliance fees paid by pharmacies, not by patients.

The unit economics support sustainability. A per-transaction fee of 50 Nigerian naira, roughly 0.03 USD, on 50,000 annual transactions per mid-sized pharmacy chain generates 2.5 million naira per chain per year. With 200 pharmacies onboarded by month 24, the platform reaches a run rate that covers its core infrastructure costs, which I estimate at 15 million naira annually based on my current operating costs for self-hosted servers, storage, and bandwidth. The machine-learning verification layer improves with each flagged counterfeit, creating a data moat that strengthens the platform's value to both pharmacies and regulators over time.

The expansion model is replicable across West Africa. Ghana, Kenya, and Uganda each have national drug regulatory authorities with the same counterfeit-drug problem and similar pharmacy-distribution structures. The platform's regulatory-compliance layer is designed with a jurisdiction-agnostic core, so adapting to a new country's reporting format is a configuration change, not a rebuild. Grand Challenges Canada's network in LMIC health innovation provides the partnerships needed to explore these adjacent markets after the Nigerian pilot proves the model.

ESSAY RESPONSE: TEAM AND CAPACITY

I am the sole founder and technical lead. My qualifications for this role are clinical and computational. I am a PCN-licensed pharmacist with a B.Pharm from the University of Ibadan and clinical experience at Ramset Pharmacy. I am also a software engineer with production experience in Linux VPS operations, CI/CD, automated backup and disaster recovery, and applied machine learning. I have built and validated predictive models in drug-resistance prediction, including TOPOLOGIX, which achieved an AUROC of 0.804 on the Platinum benchmark. I am currently enrolled in the M.Sc. Digital Health program at the Hasso Plattner Institute / University of Potsdam, which gives me access to European digital-health research networks.

The gaps in my capacity are regulatory affairs and field operations in Nigerian pharmacy chains. I am addressing these through two advisory relationships. First, I am in discussion with a former NAFDAC post-marketing surveillance officer to serve as regulatory advisor, ensuring the audit-trail design matches NAFDAC's actual reporting requirements. Second, I am in discussion with the owner of a 15-pharmacy chain in Oyo State to serve as clinical operations advisor and pilot partner. Both relationships are in early discussion stages and require formalization before the grant start date.

I will hire two additional roles with grant funding: a full-time field coordinator based in Ibadan to manage pharmacy onboarding and training, and a part-time data engineer to support the verification-model pipeline. I will remain the technical lead and product architect.

CHECKLIST

- [ ] Register on the Fluxx Portal at least 7 business days before the March 31, 2026 deadline
- [ ] Confirm eligibility as an independent researcher from Nigeria (LMIC) under GCC's current country list
- [ ] Verify whether this application falls under the general call or a specific themed call (e.g., Transition to Scale) and adjust the proposal accordingly
- [ ] Secure formal letters of support from the Oyo State Ministry of Health and the pilot pharmacy chain
- [ ] Formalize advisory agreements with the former NAFDAC officer and the pharmacy-chain owner
- [ ] Draft a detailed budget breakdown for the $1.2M pilot and expansion phase
- [ ] Prepare a pre-registration document for the verification-layer AUROC target and the three primary impact indicators
- [ ] Collect and attach evidence of prior work: TOPOLOGIX benchmark results, hERG replication study, and production infrastructure portfolio
- [ ] Confirm the M.Sc. enrollment status at HPI/Potsdam and include proof of enrollment
- [ ] Verify the current status of the co-authored Alcohol (Elsevier) paper and include as evidence of peer-reviewed output
- [ ] Prepare a data-management and privacy plan for patient health information, aligned with Nigerian data-protection regulations
- [ ] Confirm the exact submission format and word limits for all required fields on the Fluxx portal

EDITOR NOTES

- Eligibility risk: The profile lists the applicant as an independent researcher, but the venture requires a legal entity (e.g., a Nigerian company) to receive grant funds. Confirm whether GCC requires a registered entity or allows individual grantees, and if needed, register a Nigerian limited liability company before the deadline.
- The March 2026 deadline is distant; confirm the programme is still accepting applications and that the general track is open, as GCC sometimes shifts to invitation-only rounds for Transition to Scale.
- The two advisory relationships (NAFDAC officer and pharmacy-chain owner) are described as "in discussion." These must be formalized before submission; a letter of intent from each is the minimum acceptable evidence.
- The budget figure of $1.2M for pilot and expansion is an estimate. A detailed line-item budget must be built and validated against Nigerian market rates for software infrastructure, field staff salaries, and pharmacy training costs.
- The claim that the platform is the only project in the portfolio built for scaled health impact is accurate per the profile, but the applicant should be prepared to explain why the CCT and TOPOLOGIX research lines are not being submitted, in case reviewers ask about the broader portfolio.

AI Draft — Grand Challenges Canada